Using advanced imaging to assess melanoma treatment response
Interest in PET/CT Whole-body Dynamic Acquisition at FDG to Differentiate Progression/Pseudo Progression of Metastatic Melanoma Under Immunotherapy
This study is testing a new type of imaging to see if it can better tell the difference between real cancer growth and false alarms in patients with advanced melanoma who are receiving immune therapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 56 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Brest Academic / other |
| Drugs / interventions | Nivolumab, Pembrolizumab |
| Locations | 1 site (Brest, Finistere) |
| Trial ID | NCT04272658 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the effectiveness of 4D body-to-whole dynamic acquisition in FDG PET/CT scans to differentiate between true progression and pseudo-progression in patients with metastatic melanoma undergoing treatment with immune checkpoint inhibitors. The study aims to provide insights during the first therapeutic assessment of these patients, potentially improving the accuracy of treatment evaluations. By analyzing the imaging data, researchers hope to predict disease progression more reliably.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with metastatic melanoma who are being treated with anti-PD1 therapies such as Nivolumab or Pembrolizumab.
Not a fit: Patients under 18, pregnant or breastfeeding women, those with tumors other than metastatic melanoma, or individuals who refuse participation will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the ability to accurately assess treatment responses in metastatic melanoma, leading to better patient management.
How similar studies have performed: While this approach is innovative, similar studies using advanced imaging techniques have shown promise in improving treatment assessments in other cancers.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient old ≥ 18 years * With metastatic melanoma * Treated with anti-PD1 : Nivolumab or Pembrolizumab or Combo IPI-Nivo * Having formulated a non-opposition Exclusion Criteria: * \- Minor patient \< 18 years * Pregnancy or breastfeeding * Other type of tumor than metastatic melanoma * Non-eligibility for the examination * Refusal of participation
Where this trial is running
Brest, Finistere
- Hospital University ff Brest — Brest, Finistere, France (Recruiting)
Study contacts
- Principal investigator: Ronan ABGRAL, MD-PhD — Nuclear Medecine
- Study coordinator: Ronan ABGRAL, MD-PhD
- Email: ronan.abgral@chu-brest.fr
- Phone: +33 (0) 298223327
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.